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Background: To study in a phase I–II trial the maximum tolerated dose, the toxicity, and the tolerance of
adding radiotherapy to systemic chemotherapy administered preoperatively in patients with locoregionally
advanced gastric adenocarcinoma.
Patients and methods: Patients with adenocarcinoma of the stomach (T3–4Nany or TanyN+), performance
status ≤1, normal hematological, hepatic and renal functions received two cycles of cisplatin 100 mg/m2 on
day 1, 5-FU 800 mg/m2 on days 1 to 4 and leucovorin 60 mg b.i.d. on days 1 to 4 q3w, concomitantly with
radiation therapy escalated in three dose tiers (31.2, 38.4 and 45.6 Gy).
Results: Nineteen patients were accrued and 18 completed neoadjuvant therapy. Major toxicity consisted of
grade 3/4 leucopenia and mucositis in 89% and 36% of the patients, respectively. Only one episode of febrile
neutropenia was recorded. Dose level number 2 (38.4 Gy) with the chemotherapy given q4w is the recom-
mended dose level. All patients were subsequently operated and no fatalities occurred. Pathological assessment
showed one complete and eight partial responses. Two- and 3-year relapse-free survival rates were 57% and
50%, respectively. Only one patient relapsed locally. The peritoneum was the most frequent site of relapse.
Conclusions: This neoadjuvant therapeutic program is relatively well tolerated, does not seem to increase the
operative risk, and might increase the locoregional control of the disease. The frequency of peritoneal involve-
ment in relapsing patients underscores the need for a more effective systemic treatment.
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Introduction
Despite a significant decrease in its incidence over the last
70 years, gastric cancer remains a significant health problem
worldwide [1]. In Western countries, the disease is diagnosed
mostly at an advanced stage, and the cure rate of locoregionally
advanced disease remains dismal even with extensive surgery
[2, 3]. Adjuvant chemotherapy has been tested in numerous
randomized trials, but its effectiveness has not been convincingly
established thus far [4]. Furthermore, it is very likely that the
patients enrolled in these studies were highly selected. From a
nutritional point of view, it has been shown that patients often
recover slowly from total gastrectomy and are therefore unfit to
start adjuvant systemic treatment 4–6 weeks after surgery [5, 6].
Locoregional relapse is also a major problem after curative
surgery in gastric cancer. According to some series, the first site
of relapse is local or regional in up to 50% of curatively-operated
patients [7–9]. The incorporation of radiotherapy into (neo)-
adjuvant therapeutic programs might decrease the locoregional
relapse rate and thereby improve long-term results. A number of
randomized trials studying preoperative or postoperative radio-
therapy have been published, some with encouraging results
[10–15]. However, most of the studies suffered from methodo-
logical problems, making them inconclusive [16]. Recently, a
large trial in the USA comparing adjuvant radiochemotherapy
plus chemotherapy with surgery alone has clearly shown an
advantage for the adjuvant arm [17]. However, the results of this
well-designed and well-conducted trial were mitigated by the
suboptimal surgery performed in >50% of the patients enrolled.
Furthermore, this adjuvant program was relatively toxic, with
grade 3 and 4 toxicities observed in 41% and 32% of the patients,
respectively.
Problems associated with postsurgical recovery can be avoided
by the administration of systemic therapy and/or radiation prior
to the surgical procedure. Furthermore, preoperative therapy has
the theoretical advantage of treating an untouched tumor (lack of
treatment-induced resistance), with intact vascularization and
without fibrotic remodeling of the tumor bed due to surgical
trauma. These considerations might account for the higher
response rates observed when systemic therapy is administered
preoperatively [18–20].
In contrast to adenocarcinoma of the esophagus, where neo-
adjuvant radiochemotherapy has been extensively investigated,
very little has been done so far in gastric cancer with a combined-
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modality approach [21, 22]. Therefore, we conducted a phase I–II
trial to study the maximum tolerated dose (MTD), the toxicity
and the tolerance of the addition of radiotherapy to systemic
chemotherapy administered preoperatively in patients suffering
from locoregionally advanced gastric carcinomas.
Patients and methods
Consecutive patients with locally advanced adenocarcinoma of the stomach
(T3
–
4Nany or TanyN+) amenable to curative resection were enrolled in this
study. Patients were required to have a performance status ≤1, age ≤70 years
old, normal blood counts, creatinine clearance ≥60 ml/min, normal liver
function and no other serious illness or medical history.
The treatment consisted of two courses of chemotherapy combined with
radiation therapy, followed by surgery performed 50 days after the start of the
treatment program. The treatment schedule, including the radiotherapy dose
escalation, is summarized in Figure 1. Chemotherapy consisted of cisplatin
100 mg/m2 on day 1 in a 4-h i.v. infusion, followed by 5-FU 800 mg/m2/day
on days 1 to 4 in 24-h i.v. infusion and leucovorin 60 mg twice daily on days
1 to 4, to be repeated once on days 22 to 25. All patients received a standard
supportive regimen consisting of hyperhydration and antiemetics during each
course of treatment.
Radiotherapy was escalated by starting it earlier in the neoadjuvant
treatment plan as follows: for the first radiotherapy dose level, 31.2 Gy in
26 fractions (two daily fractions of 1.2 Gy at least 6 h apart, 5 days a week)
was given to six patients starting on day 22. Dose escalations to 38.4 Gy (in
32 fractions) starting on day 16, and then to 45.6 Gy (in 38 fractions) starting
on day 11 were then carried out according to tolerance. The target volume
included the tumor bed and the regional lymph nodes, adapted according
to tumor location. Before each dose escalation, at least five patients in the
previous dose tier had to have completed the treatment program with at least
28 days’ postoperative follow-up. Toxicity was assessed according to WHO
grading.
Responses were assessed by pathological examination of the resected
specimens by an experienced pathologist (M-A.B.). If grossly residual tumor
was present, the specimen was sampled according to standard procedures.
While in cases with no or only small foci of residual tumor, the presumed
tumor area was sampled in toto. A complete pathological response (pCR) was
defined by the total absence of detectable viable tumor. A partial pathological
response (pPR) was defined as residual viable tumor of a total size of
≤10 mm. Specimens not satisfying these criteria, i.e. with residual tumor of
>10 mm, were considered as not showing a significant response (pNR) and
the patients considered as non-responders (NR).
Results
Nineteen consecutive patients with clinical stage II, IIIA, IIIB
and IV (five, ten, two and two patients, respectively) were entered
in the study. All patients had had a full pretreatment work-up,
including thoraco-abdominal CT scan, bone scintigraphy, upper
gastrointestinal (GI) series and endosonography.
The results of the study are summarized in Table 1. Six, nine
and four patients were enrolled in dose tiers 1, 2 and 3, respect-
ively. In the first dose tier, all patients but one received their
treatment on schedule. In the second dose tier, six patients had
their second cycle delayed by 1 week and one by 2 weeks. In the
third dose tier, one patient had the second cycle of chemotherapy
delayed by 1 week, another by 3 weeks (febrile neutropenia),
and one refused it. Most delays were due to late hematological
recovery. Per protocol, white blood cell and platelet counts had to
be at least 3000/mm3 and 100000/mm3, respectively, before the
next cycle of chemotherapy. Grade 3/4 hematological toxicity
was observed in all but two patients, and led to only one episode of
febrile neutropenia in the third dose tier. Grade 3/4 mucositis was
observed in two of six, two of nine and three of four patients in
dose tiers 1, 2 and 3, respectively. Three of these patients (one per
dose tier) experienced concomitant grade 3 fatigue. One patient
in dose tier 2 had grade 3 nausea–vomiting. Other toxicities were
mild or moderate, not exceeding grade 2. Based on the high
incidence of grade 3/4 toxicity in the four patients included in the
last dose tier, this dose tier was considered to be the MTD. Dose
tier number 2, with the chemotherapy recycled at 4 week inter-
vals, is the recommended dose level for future phase II studies.
After completion of the neoadjuvant treatment program and
before surgery, all patients underwent a work-up with a thoraco-
abdominal CT scan, a gastroscopy and an upper GI series.
None of the patients were found to have progressed. However,
bidimensionally measurable disease was not available to allow a
reliable clinical assessment of tumor response.
All patients underwent a total or subtotal gastrectomy with D2
lymph node resection. No postoperative deaths were observed.
One patient suffered an anastomotic leak requiring surgical
drainage and prolonged hospital stay. A second patient had a
biliary peritonitis secondary to a probable duodenal leak, man-
aged conservatively. Both patients recovered fully thereafter.
Three patients were found during surgery to have minimal
peritoneal carcinomatosis (patients 7, 12 and 18). Pathological
examination of the resected specimens showed one pCR and
eight pPRs.
Overall survival and relapse-free survival curves are presented
in Figures 2 and 3, respectively, with a median follow up of
81 months. Two- and 3-year relapse-free survival rates were 57%
(95% CI 35% to 77%) and 50% (95% CI 26% to 71%), respect-
Figure 1. Treatment scheme.
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ively, while the overall 2- and 3-year survival rates were 71%
(95% CI 47% to 87%) and 59% (95% CI 36% to 79%). Ten
patients have died, nine of them after progression of their gastric
cancer. One patient died of acute erythroleukemia (AML M6)
three and a half years after inclusion in the study, without
evidence of gastric cancer relapse. The sites of relapse or residual
disease after gastrectomy are detailed in Table 1.
Discussion
Despite the small number of patients enrolled in the present
study, its results indicate that radiotherapy can be safely combined
with neoadjuvant chemotherapy in locally-advanced gastric
cancer patients. Furthermore, neoadjuvant chemoradiation seems
to be effective, as suggested by the number of pathological
reponses observed. This approach may thus be able to decrease
the high rate of locoregional relapse typically observed in this
unfavorable patient population.
The main aim of this study was to determine the dose of
radiotherapy that could be added to a relatively standard drug
combination in gastric cancer. The rationale was that potential
improvement in locoregional control by the addition of radiation
therapy should not be obtained to the detriment of systemic
therapy. Therefore, a conventional chemotherapy regimen for
gastric cancer was chosen and given at a fixed standard dosage.
The radiation was then escalated, indicating that 38.4 Gy could
be combined safely with this regimen. However, all but two
patients treated at this dose level had their second cycle of
chemotherapy delayed by 1 week (2 weeks in one case). This is
the reason why dose tier 2, with the chemotherapy recycled at
4 week intervals, is the recommended treatment program in this
setting. Dose tier 3 was considered the MTD, since all patients
but one endured significant toxicity and had prolonged delays in
chemotherapy.
This relatively intensive neoadjuvant treatment program did
not seem to increase operative risks significantly. One of the
19 patients presented with a serious complication requiring re-
operation, but no fatality was recorded. One can only speculate
whether this anastomotic leak was due to the neoadjuvant chemo-
radiation, or whether it just occurred by chance. The fistula took
several weeks to heal, and irradiation may have been partly
responsible for this delay. Surgery in an irradiated field can be
more difficult because of tissue fragility, with compromised
anastomotic healing and a higher risk of anastomotic leakage.
During our study, the surgeon and the radiation oncologist main-
tained close contact, and the planning of radiation fields regularly
took into account the surgeon’s input. In addition, the operative
approach was modified according to the neoadjuvant therapy,
Table 1. Results summary
pPR, partial pathological response; NR, pathological ‘No Response’ when criteria for pPR are not reached (see text); pCR, complete pathological 
response; TTT, treatment; NED, no evidence of disease; DOD, dead of disease; DOOC, dead of other cause; AWD, alive with disease.
Patient 
number 
Dose 
tier
Maximal 
hemato-
toxicity
Grade 3/4 
non-hematological 
toxicity
TTT delays Pathological 
response
First site of relapse Outcome 
(months) cut off : 
30.09.2001
1 1 4 Mucositis + fatigue – pPR – NED (84+)
2 1 4 – – pPR – NED (83+)
3 1 3 – – NR – NED (81+)
4 1 4 – – pCR – NED (81+)
5 1 4 Mucositis 1 week NR Peritoneum DOD (12)
6 1 3 – – NR Retroperitoneum + 
peritoneum
DOD (59)
7 2 4 – 1 week NR Peritoneum DOD (6)
8 2 3 Mucositis + fatigue 1 week pPR – DOOC (42)
9 2 3 – 1 week pPR – NED (71+)
10 2 4 – 1 week NR Peritoneum DOD (17)
11 2 2 – – pPR Retroperitoneum + 
liver
DOD (24)
12 2 3 Nausea/vomiting 2 weeks NR Peritoneum DOD (29)
13 2 3 – – NR – NED (53+)
14 2 4 Mucositis 1 week NR Peritoneum DOD (27)
15 2 3 – 1 week NR Anastomosis DOD (39)
16 3 4 Mucositis + fatigue 2nd cycle refusal pPR – NED (47+)
17 3 4 Mucositis 3 weeks pPR – NED (37+)
18 3 2 – – NR Peritoneum DOD (13)
19 3 3 Mucositis 1 week pPR Peritoneum AWD (28+)
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aiming to locate the anastomosis in a non-irradiated zone. In two
cases of proximal tumor, thoracotomy was needed. In three other
patients, distal gastrectomy had to be converted to total gastric
resection.
Several encouraging conclusions can be drawn from these
results regarding the efficacy of this treatment program. Nine out
of 19 patients presented with major responses to preoperative
therapy. It is of interest to note that seven of them are still relapse-
free 37+ to 84+ months after inclusion. This contrasts with the
10 patients considered as non-responders or poor responders to
the neoadjuvant treatment program, only two of whom are still
relapse-free 55+ and 81+ months later. In esophageal carcinoma,
it is known that pCR or near pCR to neoadjuvant therapy indic-
ates a good prognosis [23, 24]. The observation that most sur-
Figure 2. Overall survival.
Figure 3. Event-free survival.
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vivors in our study were found among responders leads us to
suspect that this might also be valid for gastric cancer, as already
reported by others [22].
The median disease-free survival of 35.5 months (CI 95%
9.5 months to not reached), and the median survival of 42.5 months
(CI 95% 18 months to not reached) are of interest, considering the
locoregionally-advanced status of the patients enrolled. How-
ever, this is certainly not conclusive because of the small size of
the population considered, which explains the very wide 95%
confidence intervals observed. Among the other encouraging
features, we can note that only one of the relapsing patients did so
locally (patient number 15). This contrasts significantly with the
high locoregional relapse rate reported by other authors, leading
us to believe that this treatment program is effective for loco-
regional disease control [7, 8].
On the downside, however, it is of concern that the great major-
ity of the relapsing patients did so in the peritoneum, and that for
seven of them it was the sole site of clinically-detectable disease
at first relapse. This finding implies that the impact of this treat-
ment program is mostly locoregional. We are still in need of more
effective chemotherapeutic regimens to decrease the incidence of
distant relapse, especially in the peritoneal cavity, which seems
to be a very common target for recurrence in locoregionally
advanced disease [25]. Promising newer chemotherapeutic
regimens incorporating taxanes or topoisomerase I inhibitors
may be worth testing in this setting [26–30].
In conclusion, we show that radiation therapy can be safely
combined to 5-FU–cisplatin in a neoadjuvant setting in loco-
regionally advanced gastric cancer, and that it seems to have an
encouraging impact on the incidence of local relapse. However,
distant failures, especially in the peritoneal cavity, remain a
major issue, underscoring the need for more effective systemic
therapy in this disease.
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